The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Open accessAbstract
Purpose: Limited data are available on the time course of treatment failures (recurrence and/or death), the nature and duration of adjuvant treatment benefit, and long-term recurrence rates in patients with resected stage II and III colon cancer. Methods: The data set assembled by the Adjuvant Colon Cancer Endpoints Group, a collection of individual patient data from 18 trials and more than 20,800 patients testing fluorouracil-based adjuvant therapy in patients with stage II or III colon cancer, was analyzed. Results: A significant overall survival (OS) benefit of adjuvant therapy was consistent over the 8-year follow-up period. The risk of recurrence in patients treated with adjuvant chemotherapy never exceeds that of control patients, signifying that adjuvant therapy cures some patients, as opposed to delaying recurrence. After 5 years, recurrence rates were less than 1.5% per year, and after 8 years, they were less than 0.5% per year. Significant disease-free survival (DFS) benefit from adjuvant chemotherapy was observed in the first 2 years. After 2 years, DFS rates in treated and control patients were not significantly different, and after 4 years, no trend toward benefit was demonstrated. This benefit was primarily driven by patients with stage III disease. Conclusion: Adjuvant chemotherapy provides significant DFS benefit, primarily by reducing the recurrence rate, within the first 2 years of adjuvant therapy with some benefit in years 3 to 4, translating into long-term OS benefit. This reflects the curative role of chemotherapy in the adjuvant setting. After 5 years, recurrence rates in patients treated on clinical trials are low, and after 8 years, they are minimal; thus, long-term follow-up for recurrence is of little value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Self-citationTrastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Self-citationLevamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,256
Self-citationKuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Self-citationA Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., & Francini, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010957 · Cited by 986
Self-citationSargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713 · cited 2×
“We have previously demonstrated that 80% of colon cancer patients who experienced recurrence in the first 8 years after surgery do so in the first 3 years.(7) These new results not only confirm this finding, but also demonstrate that the risk of recurrence continues to be low for up to 15 years of follow-up.”
MethodWolmark, N., Rockette, H., Fisher, B., Wickerham, D. L., Redmond, C., Fisher, E. R., Jones, J., Mamounas, E. P., Ore, L., & Petrelli, N. J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1879 · Cited by 689
Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., Bear, H. D., Atkins, J. N., Dimitrov, N. V., Glass, A. G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3553 · Cited by 493
Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., Fields, A. L. A., & Mayer, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2144 · Cited by 449
Self-citationO'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Erlichman, C., Shepherd, L., Moertel, C. G., Kocha, W. I., Pazdur, R., Wieand, H. S., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.295 · Cited by 417
Self-citationHazard Rate Estimation under Random Censoring with Varying Kernels and Bandwidths
Muller, H.-G., & Wang, J.-L. (1994) · Biometrics · doi:10.2307/2533197 · Cited by 340
Goldberg, R. M., Fleming, T. R., Tangen, C. M., Moertel, C. G., Macdonald, J. S., Haller, D. G., & Laurie, J. A. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00007 · Cited by 265
Self-citationSargent, D. J., Patiyil, S., Yothers, G., Haller, D. G., Gray, R., Benedetti, J., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4323 · Cited by 240
Self-citationChau, I., Allen, M. J., Cunningham, D., Norman, A. R., Brown, G., Ford, H. E. R., Tebbutt, N. C., Tait, D., Hill, M. E., Ross, P. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.041 · Cited by 172
Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer
de Gramont, A., Buyse, M. E., Abrahantes, J. C., Burzykowski, T., Quinaux, E., Cervantes, A. M. R., Figer, A., Lledo, G., Flesch, M., Mineur, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4380 · Cited by 146
Self-citationde Gramont, A., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P., Lorenzato, C., & André, T. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4007 · Cited by 131
Cutsem, E. V., Labianca, R., Hossfeld, D., Bodoky, G., Roth, A. D., Aranda, E., Nordlinger, B., Assadourian, S., Wang, K., & Cunningham, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba8 · Cited by 130
Self-citationde Gramont, A., Hubbard, J. M., Shi, Q., O’Connell, M. J., Buyse, M. E., Benedetti, J., Bot, B. M., O’Callaghan, C. J., Yothers, G., Goldberg, R. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1407 · Cited by 82
Self-citationSimultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations
Gilbert, P. B., Wei, L. J., Kosorok, M. R., & Clemens, J. D. (2002) · Biometrics · doi:10.1111/j.0006-341x.2002.00773.x · Cited by 49
Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?
Grothey, A. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1125 · Cited by 7
Self-citation
Cited by
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,404
Self-citationLocalised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.022 · Cited by 1,375
Self-citation5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y.-J., Choti, M. A., Cooper, H. S., Covey, A., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0056 · Cited by 683
Metadata
- Authors
- Sargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., Seitz, J. F., Francini, G., Haller, D., Yothers, G., Goldberg, R., & de Gramont, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-20
- Volume
- 27
- Issue
- 6
- Pages
- 872-877
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158257131
- Cited by
- 666
- References
- 21
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.